Fool - Investing News·15h ago
5 Dividend Kings Long-Term Investors Should Own for the Next 20 YearsInvestors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Abbott Laboratories(ABT)Earnings, Financials & Key Ratios
ABT•NYSE
$95.84
25.8× P/E·Price updated Jul 7, 2026
AboutAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.Show more
- Revenue$44.33B+5.7%
- EBITDA$10.79B+7.5%
- Net Income$6.52B-51.3%
- EPS (Diluted)3.72-51.3%
- Gross Margin55.51%+9.2%
- EBITDA Margin24.35%+1.7%
- Operating Margin18.16%+11.6%
- Net Margin14.72%-53.9%
- ROE12.96%-58.1%
ABT Price & Volume
Abbott Laboratories (ABT) stock price & volume — 10-year historical chart
Loading chart...
Aggressive Inorganic Growth Challenges Margin Scalability Metrics
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Expanding
Profitability:Moderate
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Legal and integration overhangs
Key Thesis Takeaways
- Abbott Laboratories is currently navigating a complex transition characterized by robust 7.8% year-over-year revenue growth in 2026Q1, yet this expansion is increasingly reliant on aggressive inorganic strategies that have elevated goodwill to $35.2 billion.
- While the company has successfully improved gross margins to 56.3%, persistent operating leverage constraints and significant acquisition-related debt suggest that future profitability may be pressured by integration costs.
- Investors should monitor the sustainability of cash conversion, as recent working capital outflows of $882 million in 2026Q1 highlight potential inefficiencies in managing the expanded asset base.
Verdict Logic
while the company maintains a 2.5% dividend yield, the high PEG ratio of 3.05 and the significant $35.2 billion goodwill concentration suggest that current valuation may not fully account for integration and leverage risks.
ABT Growth Metrics
Abbott Laboratories (ABT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.07%
5 Years5.08%
3 Years0.51%
TTM6.59%
Profit CAGR
10 Years3.96%
5 Years7.74%
3 Years-2.01%
TTM-53.52%
EPS CAGR
10 Years2.38%
5 Years8.27%
3 Years-1.65%
TTM-53.43%
Return on Capital
10 Years9.65%
5 Years12.43%
3 Years11.12%
Last Year11.71%
ABT Recent Earnings
Abbott Laboratories (ABT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 16, 2026Metric
Actual
Est
EPS
$1.15+0.9%
$1.14
Rev
$11.2B+1.5%
$11.0B
Q1 2026
Jan 22, 2026Metric
Actual
Est
EPS
$1.50+0.0%
$1.50
Rev
$11.5B-2.9%
$11.8B
Q4 2025
Oct 15, 2025Metric
Actual
Est
EPS
$1.30+0.0%
$1.30
Rev
$11.4B-0.2%
$11.4B
Q3 2025
Jul 17, 2025Metric
Actual
Est
EPS
$1.26+0.0%
$1.26
Rev
$11.1B+0.5%
$11.1B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 16, 2026 | $1.15vs $1.14+0.9% | $11.2Bvs $11.0B+1.5% |
| Q1 2026 | Jan 22, 2026 | $1.50vs $1.50+0.0% | $11.5Bvs $11.8B-2.9% |
| Q4 2025 | Oct 15, 2025 | $1.30vs $1.30+0.0% | $11.4Bvs $11.4B-0.2% |
| Q3 2025 | Jul 17, 2025 | $1.26vs $1.26+0.0% | $11.1Bvs $11.1B+0.5% |
Based on last 12 quarters of dataView full earnings history →
Latest ABT News
Recent stock market news and headlines for Abbott Laboratories (ABT)
Zacks Investment Research·1 day ago
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on ItRecently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Fool - Investing News·1 day ago
3 Stocks to Buy and Hold: The Long-Term Play for Your PortfolioThese three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.
Seeking Alpha·4 days ago
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth ConsideringAbbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
24/7 Wall Street·5 days ago
5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return PotentialPassive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
Peers Comparison
Key metrics vs top competitors for Abbott Laboratories (ABT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $95.84 | $166.94B | 25.76 | 5.67% | 14.72% | 12.96% | 2.46% | |
| $83.83 | $107.63B | 22.47 | 8.43% | 13.2% | 9.78% | — | |
| $45.30 | $67.33B | 23.35 | 19.87% | 17.23% | 14.67% | — | |
| $156.30 | $56.63B | 26.81 | 8.23% | 5.33% | 4.54% | — | |
| $22.86 | $11.8B | -13.06 | 5.72% | -9.7% | -16.5% | — | |
| $94.82 | $54.6B | 51.81 | 11.55% | 17.34% | 10.54% | — |
Compare ABT vs Peers
Abbott Laboratories (ABT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABT SEC Filings & Documents
Abbott Laboratories (ABT) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Apr 27, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 16, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when ABT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABT Frequently Asked Questions
Abbott Laboratories (ABT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Abbott Laboratories's revenue?
Abbott Laboratories (ABT) reported $45.13B in revenue for fiscal year 2025. This represents a 310% increase from $11.01B in 1996.
How fast is Abbott Laboratories growing?
Abbott Laboratories (ABT) grew revenue by 5.7% over the past year. This is steady growth.
Is ABT profitable?
Yes, Abbott Laboratories (ABT) is profitable, generating $6.28B in net income for fiscal year 2025 (14.7% net margin).
Dividend & Returns
Does ABT pay dividends?
Yes, Abbott Laboratories (ABT) pays a dividend with a yield of 2.46%. This makes it attractive for income-focused investors.
What is ABT's return on equity?
Abbott Laboratories (ABT) has a return on equity (ROE) of 13.0%. This is reasonable for most industries.
What is Abbott Laboratories's free cash flow?
Abbott Laboratories (ABT) generated $7.38B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.